Journal Review: Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes
Independent review of a New England Journal of Medicine study on VX-880 (Zimislecel), a stem cell-derived islet therapy for type 1 diabetes. Highlights include restored insulin production, 83% insulin independence at one year, and the promise of a potential cure.